Skip to main content

5 articles related to "Refractoryrelapsed Multiple Myeloma"

No matches to your query could be found. Try another search term.
No matches to your query could be found. Try another search term.
No matches to your query could be found. Try another search term.
No matches to your query could be found. Try another search term.
No matches to your query could be found. Try another search term.

Articles

Original Research

Published on 05 Mar 2021

The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma

in Cancer Immunity and Immunotherapy

Deming Duan
Keke Wang
Cheng Wei
Dudu Feng
Yonghua Liu
Qingyan He
Xing Xu
Chunling Wang
Shuping Zhao
Leili Lv

Frontiers in Immunology

doi 10.3389/fimmu.2021.609421

19,597 views
87 citations

Review

Published on 17 Mar 2025

Strategies for salvage therapy post CAR-T therapy failure in refractory/relapsed multiple myeloma patients

in Pharmacology of Anti-Cancer Drugs

Chao Min
Xiong Zhong
Yue Cui
Hanfu Zhang
Qingming Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1515555

4,938 views
1 citation

Original Research

Published on 05 Dec 2024

Prevalence of measurable residual disease in patients with refractory/relapsed multiple myeloma who reached complete response: a cross-sectional multicentric study

in Blood Cancer

Manuel Neves
Rita Gerivaz
Graça Esteves
Rui Bergantim
Gisela Ferreira
Henrique Coelho
Celina Afonso
Delfim Duarte
Anabela Neves
Helena Matos Silva

Frontiers in Hematology

doi 10.3389/frhem.2024.1480120

2,028 views

Review

Published on 24 Feb 2021

Perspectives for the Use of CAR-T Cells for the Treatment of Multiple Myeloma

in Cancer Immunity and Immunotherapy

Marcin Jasiński
Grzegorz W. Basak
Wiesław W. Jedrzejczak

Frontiers in Immunology

doi 10.3389/fimmu.2021.632937

10,241 views
19 citations

Systematic Review

Published on 03 Dec 2020

Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials

in Pharmacology of Anti-Cancer Drugs

Xinrong Xiang
Qiao He
Yang Ou
Wen Wang
Yu Wu

Frontiers in Pharmacology

doi 10.3389/fphar.2020.544754

11,032 views
21 citations